Pacira BioSciences Reports Q2 2025 Financial Results: $181.1M Revenue, Net Loss of $4.8M

Pacira BioSciences reported Q2 2025 financial results with total revenues of $181.1 million and a net loss of $4.8 million. The company highlighted its progress in advancing its 5×30 growth strategy, expanding market adoption for its flagship product, EXPAREL. Net product sales were $142.9 million for EXPAREL, $31.3 million for ZILRETTA, and $5.6 million for iovera°. Pacira achieved an adjusted EBITDA of $54.3 million and non-GAAP net income of $36.0 million.

Pacira BioSciences, Inc. (PCRX) reported its second quarter (Q2) 2025 financial results, showing mixed performance with total revenues of $181.1 million and a net loss of $4.8 million. The company highlighted its progress in advancing its 5×30 growth strategy, expanding market adoption for its flagship product, EXPAREL. Net product sales for EXPAREL were $142.9 million, ZILRETTA sales were $31.3 million, and iovera° sales were $5.6 million. Pacira achieved an adjusted EBITDA of $54.3 million and non-GAAP net income of $36.0 million [1].

Pacira's CEO Frank Lee expressed optimism about the company's performance, stating, "We’re entering the second half of the year with strong momentum and a clear focus on further accelerating growth." The company also reported significant milestones, including surpassing 50% enrollment in a Phase 2 study of PCRX-201 for osteoarthritis and securing favorable patent rulings [2].

Pacira entered into a strategic collaboration with Johnson & Johnson MedTech to expand the market reach of ZILRETTA, leveraging its specialized early intervention sales force to co-promote the treatment to existing and new customers. The company also optimized its manufacturing process for EXPAREL, improving gross margins [3].

Despite the mixed financial performance, Pacira's stock experienced a slight decline during regular trading hours but rebounded in aftermarket trading, increasing by 3.53% to $23.75. The company narrowed its full-year revenue guidance to between $730 million and $750 million and raised its gross margin guidance to 78%-80% [1].

References:
[1] https://www.tipranks.com/news/company-announcements/pacira-biosciences-reports-q2-2025-financial-results
[2] https://www.ainvest.com/news/pacira-biosciences-q2-2025-earnings-call-transcript-key-takeaways-2508/
[3] https://www.biospace.com/press-releases/pacira-biosciences-reports-second-quarter-2025-financial-results